Dr. Prachi Mehndiratta, MD

Dr. Mehndiratta practices at University of Maryland Medical Center in Baltimore, Maryland, part of University of Maryland Medical System.

Dr. Mehndiratta's NPI, 1104057900, was assigned on July 29, 2009. Dr. Mehndiratta holds Virginia license 0101253343.

Dr. Mehndiratta's primary practice is University of Maryland Medical Center, at 22 South Greene Street, Baltimore, MD 21201 in Baltimore City. The practice phone is (410) 328-8667.

Dr. Mehndiratta's primary practice is University of Maryland Medical Center in Baltimore, Maryland, part of University of Maryland Medical System. Dr. Mehndiratta is also affiliated with University of Maryland Rehabilitation & Orthopaedic Institute. The medical group on file is University of Maryland Neurology Associates, P.A.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Mehndiratta practices, 2 sites in all. Vendor and product names are available with a free account.

Neurology is Dr. Mehndiratta's primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Dr. Mehndiratta is licensed in Virginia.

CMS data shows 151 Medicare services from Dr. Mehndiratta across 5 procedure codes in 2024, for 99 Medicare patients. Medicare paid $14,180 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 99 Medicare patients who saw Dr. Mehndiratta in 2024. The largest group is 65 to 74, with 45 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 31% are also on Medicaid. Their average risk score is 1.88, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Mehndiratta's median patient age at 65, with 50% women.

In 2024, Dr. Mehndiratta wrote 78 Medicare Part D claims for 20 patients. 69% of them were for generic drugs. CMS names the drug for 41 of them, across 2 drugs with 11 or more claims each, at $14,952 in total drug cost. In 2023, CMS named 19 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Mehndiratta for performance year 2024, reported as part of a group. Dr. Mehndiratta accepts Medicare assignment, so Medicare's approved amount is taken as full payment.